Program Overview
Genetic cardiomyopathies and channelopathies (GCMs) account for an estimated 20% of all heart failure cases in the U.S., yet fewer than 2% of eligible patients are currently tested. This presentation will describe the REIMAGINE-HF Phase I Initiative, a nationwide, society-governed descriptive analysis developed under the Heart Failure Society of America (HFSA) in collaboration with Labcorp/Invitae. Using de-identified, aggregate-level data from over 248,000 patients tested across the U.S. from 2015–2025, we will review the rapid 35-fold expansion of cardio-genetic testing volume (CAGR 35%), a consistent patient-level diagnostic yield of approximately 22%, and the leading actionable genes identified (MYBPC3, TTN, MYH7, KCNQ1, TTR). The session will also highlight critical access and representation gaps including a 3.2-fold urban-to-rural testing disparity and underrepresentation of Black and Hispanic patients relative to their burden of disease, and outline how the REIMAGINE-HF dashboard infrastructure will inform Phase II implementation pilots aimed at equitable, guideline-concordant GCM screening.
Target Audience
This activity is intended for physicians, APPs, nurses, pharmacists, pharmacologists, trainees, fellows.
Learning Objectives
Following this activity, participants will be better able to:
- Describe the current landscape of cardio-genetic testing utilization in U.S. clinical practice, including the decade-long growth trajectory and compound annual growth rate (CAGR) observed from 2015–2025.
- Identify the diagnostic yield of cardio-genetic testing at the patient level and recognize the leading actionable genes — including MYBPC3, TTN, MYH7, KCNQ1, and TTR — and their clinical implications for heart failure management.
- Recognize the geographic and demographic disparities in cardio-genetic testing access, including the urban-to-rural testing gap and underrepresentation of Black and Hispanic patients relative to their heart failure disease burden.
Agenda
Welcome and Introductions
Amin Yehya, MD, MS, HF-Cert
Phase 1: Background RE-Imagine HF
Melvin Echols, MD, MSCR, FHFSA and Mustafa Ahmed, MD
Phase 2: From Imagination to Implementation
Ana Morales, MS, CGC
Phase 3: Implementation to Real World Data
Anjali Owens, MD
Panel Discussion
Faculty
Amin Yehya, MD, MS, HF-Cert, Sentara Healthcare, Norfolk, VA
Melvin Echols, MD, MSCR, FHFSA, Morehouse School of Medicine, Atlanta, GA
Mustafa Ahmed, MD, The University of Florida Health, Gainesville, FL
Ana Morales, MS, CGC, Geisinger Health System, Danville, PA
Anjali Owens, MD, University of Pennsylvania, Philadelphia, PA
Faculty Disclosures
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.
Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.
The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:
Melvin Echols, MD, MSCR, FHFSA
Shauna Wheeler, MSL (CE Reviewer)
The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:
- Mustafa Ahmed, MD – Advisory Panel: EVAHEART INC
- Ana Morales, MS, CGC – Employee: Invitae (Ended); Consultant: Everygene (Ended), Strandbio (Ended)
- Anjali Owens, MD – Consultant: Alexion Pharmaceuticals, Bayer AG, Bristol-Myers Squibb, Cytokinetics, Edgewise, Lexeo, Tenaya Therapeutics, Pfizer (Ended)
- Amin Yehya, MD, MS, HF-Cert – Advisory Panel: Bayer AG, Bridgebio, Kestra, Merck, Novo Nordisk, Nuwellis; Speaker’s Bureau: AstraZeneca, Bayer AG, Bridgebio, Kestra, Merck, scPharmaceuticals
Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
Accreditation Statement - THIS IS THE UPDATED VERSION FROM SHAUNA
In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum of 1.00 contact hours.
The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.00 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): UAN JA4008267-0000-26-003-L01-P (live); UAN JA4008267-0000-26---4-H01-P (home study)
The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
This activity is approved for 1.00 contact hours (0.10 CEUs) of general continuing education for health care professionals.
Successful completion of this activity includes the completion of the post-course evaluation.
Important Dates
Originally recorded June 4, 2026